Fred Hassan, Warburg Pincus Partner & Managing Director, discusses the issue of drug pricing for consumers in the wake of the Mylan EpiPen pricing saga.
CNBC's Meg Tirrell speaks to former Teva CEO Jeremy Levin about drug-price hikes, and why he thinks the pharmaceutical system is in need of change.
Dr. Ezekiel Emanuel, University of Pennsylvania Chair of Medical Ethics & Health Policy, weighs in on the drug pricing debate in the wake of Mylan's EpiPen pricing saga.
CNBC's Meg Tirrell reports the latest on Mylan following the announcement that it will release a generic version of its EpiPen.
Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."
Brian Stutland, Equity Armor Investments CIO, shares his bullish take on the health care sector, amid all the political rhetoric surrounding Mylan. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports on Mylan's decision to create a "generic" of its own product, the Epipen.
Former FDA Deputy Commissioner Dr. Scott Gottlieb, who's with the American Enterprise Institute, discusses what's wrong with the US health care system.
Steve Brill, lawyer and author of "America's Bitter Pill: Money, Politics, Backroom Deals and the Fight to Fix our Broken Healthcare System" discusses what can be done to make things right with America's health care system.
CNBC's Meg Tirrell reports on Mylan's decision to launch a generic EpiPen as a way of cutting the cost of the treatment.
Amid Mylan launching an EpiPen generic alternative, the “Fast Money Halftime Report” traders and CNBC’s Jim Cramer share their take on Mylan and the biotech sector.
Mylan, Herbalife and T-Mobile are making headlines this Monday morning.
The pharmaceutical company will offer patients a two-pack carton at half price of the branded version.
Dr. Josh Sharfstein, Johns Hopkins University and Former FDA official, discusses the role of the FDA in drug pricing and competition in the pharmaceutical space.
CNBC's Meg Tirrell reports on the fears in the biotech market following the Mylan EpiPen pricing saga, as well as the news that Mylan will launch a generic EpiPen auto-injector.
EpiPen maker Mylan announcing it will launch a generic epinephrine auto-injector with a list price of $300 for a two pack. The "Squawk Box" crew discusses the news.
Linette Lopez, Business Insider Senior Finance Editor, explains how further price hikes on the EpiPen could make a lot of money for Mylan CEO Heather Bresch. CNBC's Meg Tirrell weighs in.
David Martin, M-CAM Founder, discusses the EpiPen pricing saga and his view that the patent office gave Mylan an unjustified monopoly on the drug.
Amid the Mylan EpiPen pricing saga, should there be greater regulation on the pharmaceuticals industry? Former Vermont Governor Howard Dean and CNBC Senior Contributor Larry Kudlow debate the issue.
CNBC’s Meg Tirrell reports the latest on Mylan prices and the drug price blame game.